Switzerland-based RetinAI Medical will collaborate with Novartis Pharma in a multi-year agreement which will see RetinAI’s artificial intelligence tools employed to support multiple projects in ophthalmology. Both companies have previously worked successfully on pilot projects in this disease area.
The first project under the new Master Agreement will support a multi-centre international clinical study involving patients with neovascular age-related macular degeneration. The study is designed to investigate the influence of optical coherence tomography image solutions using Artificial Intelligence on the assessment of disease activity. The study will be conducted in several clinical centres in Europe and Canada, involving more than 500 patients.
For this study, RetinAI will provide its CE-marked web-based software platform, RetinAI Discovery, a data management platform to efficiently process data at scale across imaging platforms and devices. The Discovery platform is used by professionals to navigate imaging data, compute imaging biomarkers and track changes over time for some of the most common forms of eye diseases.
Dr Carlos Ciller, CEO of RetinAI, commented: “RetinAI is excited to expand and intensify our partnership with Novartis. Our Discovery platform and AI tools are enablers to increase efficiency in research and clinical studies and we expect they can also improve medications and treatments for patients.”